USFDA completes inspection at Unit VII of Aurobindo Pharma

05 Aug 2022 Evaluate

The United States Food and Drug Administration (USFDA) has completed inspection at Unit VII of Aurobindo Pharma. The Company’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an Establishment Inspection Report (EIR) mentioning the inspection a Voluntary Action Initiated (VAI) from the USFDA and with this inspection is concluded.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1102.05 18.45 (1.70%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.